Evaluation of Behavior, Executive Function, Neurotransmitter Function and Genomic Expression Kuvan Nonresponders

Interested in this Trial?

Contact Us

Trial Status Completed

Trial Identifier

NCT01274026

Condition

Phenylketonuria, Behavior and Behavior Mechanisms, PAH Gene Expression

The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.

Trial Summary

This observational study seeks to establish evidence:

1. that physiologic changes, unrelated to effect on the Phenylalanine Hydroxylase (PAH) enzyme, occur in Phenylketonuria (PKU) patients who are treated with sapropterin (Kuvan®) therapy,
2. that these changes may be caused by enhanced neurotransmitter synthesis in the brain or an upregulation of gene expression (increasing the ability of genes to produce functional enzymes),
3. and that beneficial changes in behavior and cognition, especially executive functioning skills may result.

The objective of this study is to correlate any change in behavior and executive function skills of PKU patients who are non-responsive to sapropterin effect on the PAH enzyme, as defined by lowered blood PHE levels, with urine neurotransmitter levels and broad gene expression prior to and after sapropterin administration.

Expected outcomes would include evidence of sapropterin effects on upregulation of enzymes other than PAH that control neurotransmitter synthesis, and any resulting correlation with behavioral and cognitive changes.

The investigators hope this study will inform further detailed investigations into the biochemical and molecular actions of sapropterin (Kuvan®) that lead to increased understanding of possible treatment effects beyond a lowered blood PHE response.

Eligibility Criteria

Birth Sex

All

Age

2 Years to 21 Years

Healthy Volunteers

Yes

Drug/Treatment:

sapropterin dihydrochloride

Study Type:

Observational

Number of Participants:

21

Study Started:

2011-01

Study Updated:

2023-08-14

Trial Locations

  • Tulane University Health Science Center

    New Orleans, Louisiana, United States

Inclusion Criteria

  • established Hayward Genetics Center patients:
  • confirmed diagnosis of PKU,
  • aged 2-21 years,
  • not responsive to sapropterin with decreased blood PHE levels Subsequent to the start of the study inclusion criteria were amended: the upper limit of age was omitted, and a limited number of patients who were naive to sapropterin were recruited.

Exclusion Criteria

  • pregnancy
  • preexisting cognitive disorder or concurrent disease that would interfere with participation,
  • documented equal to or greater than 20% decrease in blood PHE levels as a response to sapropterin administration,
  • receiving neurotransmitter supplementation or medication for attention deficit hyperactivity disorder (ADHD),
  • received sapropterin therapy in the 2 months prior to the stud

Contact BioMarin Clinical Trials

Please complete and submit the following form to express interest in participating and request more information about one of our clinical trials.

By completing this form and clicking the send button, you understand and hereby consent to storage of your personal information, including within the United States and Europe, which will be accessible by BioMarin for purposes such as responding to your request, quality control, fulfilling compliance obligations, and assisting with products, services, or clinical trials. Depending on where you live, you may have the right to request access to, removal, or correction of your personal information held by BioMarin. You may submit your request via the contact information and/or webform located within the full BioMarin Privacy Policy.

*required fields

"*" indicates required fields

This field is hidden when viewing the form
This field is hidden when viewing the form